News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xechem UK Ltd. (XKEM.OB) Expands Its Arsenal For Treating Sickle Cell Disease; Licenses New Anti-Sickling Agent From Virginia Commonwealth University



12/9/2005 10:43:01 AM

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Dec. 9, 2005--Xechem International, Inc. (OTC BB: XKEM) Xechem International announced today that it has acquired the exclusive, worldwide licensing rights to a new five-membered heterocyclic anti-sickling compound from Virginia Commonwealth University (VCU), Richmond, VA. Early research has shown this anti-sickling agent to be a highly effective and relatively non-toxic treatment for Sickle Cell Disease (SCD). The new compound further expands Xechem's existing portfolio of products to be used in the fight against Sickle Cell Disease.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES